Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Insights into the CARDAMON trial

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, shares insights into the Phase II CARDAMON trial (NCT02315716) which compared upfront autologous stem cell transplantation (autoSCT) versus carfilzomib-cyclophosphamide-dexamethasone (CarCyDex) consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.